According to a recent LinkedIn post from Draig Therapeutics, the company plans to present new data on DT-101 at the American Society of Clinical Psychopharmacology Annual Meeting in Miami in May 2026. The post highlights that the data come from a first-in-human Phase 1 trial of DT-101, described as a novel AMPA receptor positive allosteric modulator, and emphasizes favorable tolerability and functional biomarker findings.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post notes that the company will feature an oral presentation on May 26, 2026, followed by two poster presentations on May 28, 2026, indicating multiple scientific touchpoints with the neuropsychiatric community. For investors, the planned disclosures suggest progress in early clinical development that, if well received, could support Draig Therapeutics’ positioning in CNS drug innovation and potentially enhance prospects for future partnering or financing.